CCSD Code M0814: Open Biopsy of Native Kidney

Key Takeaways

CCSD code M0814 describes an open surgical biopsy of a native (non-transplanted) kidney, distinct from percutaneous approaches.

Pre-authorisation from UK private medical insurers is typically required before performing this procedure.

Accurate documentation of clinical indication, operative technique, and histopathology referral is essential for successful claims.

Associated anaesthesia and histopathology laboratory codes must be billed separately from M0814.

Healthcode is the standard electronic submission platform for M0814 claims across major UK PMIs.

Renal biopsy is one of nephrology’s most diagnostically valuable procedures – yet billing it correctly in UK private practice is rarely straightforward. CCSD code M0814 open biopsy native kidney is the designated code for this open surgical approach, and understanding its precise scope is the foundation of accurate claims submission. Whether you are a urologist, nephrologist, or practice manager handling private medical insurance (PMI) claims, the distinction between this code and percutaneous alternatives determines whether your claim is processed cleanly or returned for clarification.

This guide covers every dimension of CCSD code M0814 open biopsy native kidney relevant to private practice billing: the procedure definition, clinical indications, documentation standards, associated add-on codes, insurer-specific requirements, and the Healthcode submission workflow. Reimbursement rates are not quoted here, as fee schedules are updated periodically and must be verified directly with each insurer. For a broader overview of CCSD coding in UK private practice, the Pabau Bupa CCSD codes guide provides a useful reference point.

CCSD Code M0814 Open Biopsy Native Kidney: Procedure Overview

CCSD code M0814 open biopsy native kidney designates an open surgical procedure in which renal parenchymal tissue is obtained through a formal incision, rather than by percutaneous needle guidance. The CCSD official schedule uses the qualifier “native” to specify that this code applies exclusively to non-transplanted kidneys. Transplant kidney biopsies carry separate coding designations. This distinction is not administrative formality – it reflects a genuine difference in surgical complexity, anaesthetic requirements, and clinical risk profile.

Open renal biopsy is classified within the Urology section of the CCSD schedule, reflecting the surgical discipline most commonly responsible for performing the procedure. Nephrologists who perform percutaneous biopsies under ultrasound guidance use a different code. Understanding which code applies requires knowing how the biopsy was physically performed, not just why it was performed.

CCSD Code M0814: Surgical Approach and Scope

The open approach involves a formal surgical incision – typically a flank or posterior lumbotomy approach – giving the surgeon direct visualisation of the renal cortex. This level of access is reserved for cases where percutaneous biopsy is contraindicated, has failed, or where the lesion’s location requires open exposure for safe sampling. The procedure is performed under general or regional anaesthesia, which is billed separately using the applicable CCSD anaesthesia codes.

Because claims management software in UK private practice needs to correctly capture procedure complexity to support accurate billing, the surgical narrative in operative notes must describe the incision type, approach, and method of tissue acquisition. A vague reference to “kidney biopsy” without specifying the open surgical route will almost certainly prompt an insurer query.

Open vs Percutaneous Renal Biopsy: Key Code Distinctions

The CCSD schedule differentiates surgical approach types explicitly. Open biopsy and percutaneous (needle) biopsy are assigned separate codes because they represent materially different procedures in terms of theatre time, anaesthetic requirement, hospital stay, and clinical risk. Submitting M0814 for a procedure actually performed percutaneously – or vice versa – constitutes a coding error that may result in claim rejection or, in more serious cases, an audit query from the insurer.

Percutaneous renal biopsy uses ultrasound or CT guidance to direct a needle into the renal parenchyma without open incision. It is typically performed under local anaesthesia with sedation, carries a shorter recovery time, and is coded differently under the CCSD schedule. When documenting procedure type for billing, the operative or procedure report should unambiguously state which approach was used before the claim is submitted through Healthcode.

Clinical Indications for CCSD Code M0814 Open Biopsy Native Kidney

Open renal biopsy is not a first-line diagnostic intervention. Clinicians may consider it when percutaneous approaches are contraindicated or have been unsuccessful, when the clinical picture demands tissue diagnosis that cannot be obtained by less invasive means, or when the procedure is being performed in conjunction with another open abdominal or retroperitoneal operation. The clinical indication documented in the patient record must support the choice of open approach specifically.

Common clinical scenarios where CCSD code M0814 open biopsy native kidney may be appropriate include:

• Glomerulonephritis: When histopathological confirmation is needed to guide immunosuppressive therapy and percutaneous biopsy is not feasible due to coagulopathy or anatomical factors.
• Nephrotic syndrome of uncertain aetiology: Where tissue diagnosis will materially change management and the patient cannot safely undergo a needle biopsy.
• Renal neoplasm: In cases where a solid or complex renal mass requires tissue sampling and the lesion’s characteristics make percutaneous access technically inadvisable.
• Chronic kidney disease (CKD) with uncertain cause: Particularly where early-stage diagnosis may alter treatment trajectory and percutaneous approaches have been declined or failed.
• Failed or inconclusive percutaneous biopsy: Where prior needle attempts have yielded non-diagnostic tissue samples.

Clinical indications must align with current guidance from the Care Quality Commission and the treating clinician’s documented reasoning. Insurers may request supporting clinical notes to verify that the open approach was justified. The British Association of Urological Surgeons (BAUS) and the UK Kidney Association provide specialty-level guidance on procedure selection that can inform this documentation.

CCSD Code M0814 Documentation Requirements

Documentation failures are the leading cause of avoidable claim delays for surgical procedures in UK private practice. For CCSD code M0814 open biopsy native kidney, the minimum documentation set covers four areas: pre-procedure clinical justification, operative report, histopathology referral, and post-procedure follow-up. Each element serves a distinct purpose in the claims review process.

CCSD Code M0814 Pre-Authorisation Requirements

Open surgical procedures routinely require prior authorisation from UK private medical insurers. Pre-authorisation for CCSD code M0814 open biopsy native kidney should be obtained before the procedure is performed, not after. Each insurer manages this process differently: Bupa’s provider code search tool allows practitioners to verify whether a procedure requires pre-authorisation and check the applicable fee schedule. AXA Health, Vitality Health, and Aviva each maintain separate pre-authorisation processes and fee structures that must be verified directly.

Pre-authorisation requests typically require the insurer’s member number, the proposed CCSD code, a brief clinical summary supporting the procedure, and confirmation of the planned hospital or treatment centre. Submitting an incomplete request is the most common reason for authorisation delays. Always retain the authorisation reference number before proceeding – claims submitted without a valid reference are routinely held pending manual review.

Policies differ between insurers and may change without advance notice. The guidance above reflects the general approach used by major UK PMIs, but practitioners should verify current requirements directly with each insurer before submission. The Vitality Health fee finder and the Aviva fee schedule provide code-level detail that can support pre-authorisation preparation.

Healthcode Submission for CCSD Code M0814

Healthcode is the standard electronic claims submission platform used by UK private practitioners to route claims to PMIs. For CCSD code M0814 open biopsy native kidney, the claim submitted via Healthcode must include the correct code, the procedure date, the treating clinician’s GMC number, and the authorisation reference obtained during pre-authorisation. Any mismatch between the authorised code and the submitted code will trigger a manual review or rejection.

Operative reports should be available to attach or reference at the point of submission. Some insurers request a copy of the operative note as standard for surgical procedures above a certain complexity threshold. Private practice management systems that integrate with Healthcode can reduce the administrative burden of preparing and submitting these claims by pulling relevant patient and procedure data directly into the submission workflow.

Simplify CCSD Billing in Your Private Practice

Pabau integrates with Healthcode to support accurate CCSD claims submission, pre-authorisation tracking, and clinical documentation – all within one practice management platform.

Book a demo

Associated CCSD Codes for Open Biopsy Native Kidney Procedures

M0814 covers the primary surgical procedure only. Several additional elements of care carry separate CCSD codes that must be billed independently. Conflating these add-on procedures with the primary code – or omitting them entirely – will either result in under-reimbursement for the practice or trigger a bundling query from the insurer. The most clinically significant associated codes fall into two categories: anaesthesia and histopathology laboratory analysis.

CCSD Code M0814 Anaesthesia Add-On Codes

Open renal biopsy requires general or regional anaesthesia, which is billed by the anaesthetist using the relevant CCSD anaesthesia codes. The primary surgeon’s claim using CCSD code M0814 open biopsy native kidney covers only the surgical component. The anaesthetist submits a separate claim for their role. Where an anaesthetist is not independently billing – for example, in some private hospital settings – the practice should confirm the local arrangement to avoid double-billing or under-claiming.

Anaesthesia codes in the CCSD schedule are typically structured around procedure complexity and time. The anaesthetist should have access to the operative note to ensure their code selection aligns with the actual procedure performed. Any discrepancy between the surgical and anaesthetic codes submitted for the same episode may prompt an insurer query about the procedures billed.

Histopathology Laboratory Codes for Renal Biopsy

Tissue obtained during an open renal biopsy must be sent for histopathological analysis, which is the primary diagnostic purpose of the procedure. Laboratory analysis attracts its own CCSD codes, billed by the pathology laboratory rather than the operating surgeon. The specimen request form and pathology report must correspond to the procedure date and patient episode recorded in the primary claim.

For private GP and specialist clinics managing the full care episode, ensuring that the histopathology laboratory uses correct CCSD coding – and that their invoice is aligned with the clinical record – reduces the risk of episode-level queries from insurers during annual audits. Some insurers cross-reference surgical and laboratory claims for the same patient episode as part of routine billing verification.

CCSD Code M0814 Billing and Reimbursement in Private Practice

The billing workflow for CCSD code M0814 open biopsy native kidney in UK private practice follows the standard PMI claims pathway, but with several points where urology and nephrology practices commonly encounter delays or denials. Understanding those friction points before submission is more efficient than resolving them after the fact.

Insurer-Specific Guidelines for CCSD Code M0814

Major UK private medical insurers – Bupa, AXA Health, Vitality Health, Aviva, WPA, and Healix – each maintain their own fee schedules based on the CCSD code set. The WPA medical fees schedule and the Healix fee schedule provide CCSD-based reimbursement structures that practitioners can reference to verify applicable fees. Because these schedules are updated periodically, the figures applicable at the time of service must be confirmed before the procedure, not assumed from a prior episode.

Bupa’s pre-authorisation process for surgical procedures requires the treating clinician to be on Bupa’s recognised provider list. Claims submitted by non-recognised providers may be processed at a reduced rate or declined. AXA Health similarly maintains a recognised specialist network, and submission via Healthcode from a recognised provider status is the most reliable route to timely settlement. Private practice billing in the UK requires active management of insurer recognition across all major PMIs – not just the two or three most frequently encountered.

Common Denial Reasons for Open Biopsy Native Kidney Claims

Claims for open renal biopsy in private practice are denied for a predictable set of reasons. Knowing these patterns in advance allows practices to build pre-submission checks into their workflow rather than responding to rejections reactively.

The most frequent denial triggers include: lack of pre-authorisation or an expired authorisation reference; mismatch between the authorised CCSD code and the submitted code; incomplete operative notes that fail to specify the open surgical approach; and missing clinical justification for the open (rather than percutaneous) approach. Secondary denials occur when anaesthesia or histopathology codes are bundled into the primary claim rather than submitted separately.

Practices using integrated claims management software can apply validation rules at the point of submission to catch the most common errors before they reach the insurer. For CCSD code M0814 open biopsy native kidney specifically, a pre-submission checklist should verify: authorisation reference present, open approach documented in operative note, primary code M0814 used (not a percutaneous equivalent), and anaesthesia and laboratory codes excluded from the primary submission.

Expert Picks

Need to understand how CCSD codes fit into private practice billing more broadly? Pabau’s Bupa CCSD Codes guide covers the full CCSD code set used in UK private medical insurance billing, including code structure and insurer submission requirements.

Looking to build a stronger documentation workflow for surgical claims? Pabau’s claims management software supports CCSD billing workflows with Healthcode integration, pre-authorisation tracking, and clinical note capture for UK private practices.

Managing a urology or nephrology private practice and need broader operational support? Benefits of private practice outlines the operational and financial considerations for running an effective independent specialist clinic in the UK.

Conclusion

CCSD code M0814 open biopsy native kidney is a specific and well-defined procedure code within the CCSD schedule, but accurate billing requires more than knowing the code number. The open surgical qualifier, the native kidney distinction, the mandatory pre-authorisation workflow, and the need to separately code anaesthesia and histopathology laboratory components all contribute to a billing process that rewards preparation and penalises assumption.

For UK private practitioners in urology and nephrology, the most effective approach is to build a structured pre-submission checklist into every episode involving this code – verifying authorisation status, operative documentation, and associated code completeness before the claim is submitted through Healthcode. Insurers including Bupa, AXA Health, Vitality, Aviva, WPA, and Healix each apply their own fee schedules and review criteria, which must be confirmed directly for each claim.

Reviewed against current CCSD schedule guidance, Healthcode submission standards, and major UK PMI pre-authorisation requirements.

Frequently Asked Questions